Table 2.

HRs for serum lipid levels predicting risk of biochemical recurrence after radical prostatectomy

Total cholesterol< 200 mg/dL≥ 200 mg/dLContinuousa
 UnadjustedRef.1.13 (0.90–1.43), P = 0.2941.02 (0.98–1.05), P = 0.365
 AdjustedbRef.1.09 (0.85–1.39), P = 0.4931.02 (0.98–1.05), P = 0.407
LDL< 130 mg/dL≥ 130 mg/dLContinuousa
 UnadjustedRef.1.03 (0.81–1.31), P = 0.8241.00 (0.96–1.03), P = 0.832
 AdjustedbRef.1.01 (0.78–1.30), P = 0.9440.99 (0.95–1.04), P = 0.768
HDL≥ 40 mg/dL< 40 mg/dLContinuousa
 UnadjustedRef.1.12 (0.89–1.41), P = 0.3390.99 (0.92–1.07), P = 0.854
 AdjustedbRef.1.11 (0.87–1.41), P = 0.4020.97 (0.89–1.04), P = 0.378
Triglycerides< 150 mg/dL≥ 150 mg/dLContinuousa
 UnadjustedRef.1.15 (0.91–1.46), P = 0.2501.02 (1.01–1.03), P = 0.006
 AdjustedbRef.1.35 (1.05–1.74), P = 0.0201.02 (1.01–1.04), P < 0.001

NOTE: Cells display HR (95% CI), P value.

  • aHRs are for every 10 mg/dL increase.

  • bHRs are adjusted for age, race, preoperative PSA, year of surgery, BMI, surgical center, postoperative statin use, pathologic Gleason score, prostate weight, positive surgical margins, extracapsular extension, and seminal vesicle invasion.